Growth Metrics

Nektar Therapeutics (NKTR) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$35.0 million.

  • Nektar Therapeutics' Income towards Parent Company rose 558.33% to -$35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.4 million, marking a year-over-year increase of 3263.14%. This contributed to the annual value of -$119.0 million for FY2024, which is 5689.72% up from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Income towards Parent Company is -$35.0 million, which was up 558.33% from -$39.2 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Income towards Parent Company ranged from a high of $7.2 million in Q4 2024 and a low of -$159.1 million during Q2 2022
  • Over the past 5 years, Nektar Therapeutics' median Income towards Parent Company value was -$52.4 million (recorded in 2024), while the average stood at -$74.5 million.
  • Per our database at Business Quant, Nektar Therapeutics' Income towards Parent Company crashed by 5689.88% in 2021 and then soared by 11719.15% in 2024.
  • Nektar Therapeutics' Income towards Parent Company (Quarter) stood at -$146.9 million in 2021, then skyrocketed by 54.66% to -$66.6 million in 2022, then surged by 36.82% to -$42.1 million in 2023, then skyrocketed by 117.19% to $7.2 million in 2024, then tumbled by 583.66% to -$35.0 million in 2025.
  • Its Income towards Parent Company stands at -$35.0 million for Q3 2025, versus -$39.2 million for Q2 2025 and -$46.4 million for Q1 2025.